These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28786865)

  • 1. Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn's Disease.
    Kariyawasam VC; Ward MG; Blaker PA; Patel KV; Goel R; Sanderson JD; Irving PM
    Inflamm Bowel Dis; 2017 Sep; 23(9):1555-1565. PubMed ID: 28786865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease.
    Luber RP; Dawson L; Munari S; Kariyawasam VC; Martin C; Gibson PR; Sparrow MP; Ward MG
    J Gastroenterol Hepatol; 2021 Apr; 36(4):990-998. PubMed ID: 32881046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
    Hisamatsu T; Kato S; Kunisaki R; Matsuura M; Nagahori M; Motoya S; Esaki M; Fukata N; Inoue S; Sugaya T; Sakuraba H; Hirai F; Watanabe K; Kanai T; Naganuma M; Nakase H; Suzuki Y; Watanabe M; Hibi T; Nojima M; Matsumoto T;
    J Gastroenterol; 2019 Oct; 54(10):860-870. PubMed ID: 31041545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines.
    Bar-Yoseph H; Waterman M; Almog R; Billiet T; Vermeire S; Ungar B; Yanai H; Dotan I; Ben-Horin S; Chowers Y
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):69-75. PubMed ID: 27404966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn's Disease.
    Chalhoub JM; Rimmani HH; Gumaste VV; Sharara AI
    Inflamm Bowel Dis; 2017 Aug; 23(8):1316-1327. PubMed ID: 28719541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.
    Kopylov U; Al-Taweel T; Yaghoobi M; Nauche B; Bitton A; Lakatos PL; Ben-Horin S; Afif W; Seidman EG
    J Crohns Colitis; 2014 Dec; 8(12):1632-41. PubMed ID: 25067824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?
    Reenaers C; Louis E; Belaiche J; Seidel L; Keshav S; Travis S
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1040-8. PubMed ID: 23061650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.
    Matsumoto T; Motoya S; Watanabe K; Hisamatsu T; Nakase H; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    J Crohns Colitis; 2016 Nov; 10(11):1259-1266. PubMed ID: 27566367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease.
    Poon SS; Asher R; Jackson R; Kneebone A; Collins P; Probert C; Dibb M; Subramanian S
    J Crohns Colitis; 2015 Aug; 9(8):640-6. PubMed ID: 25968584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
    Hoentjen F; Seinen ML; Hanauer SB; de Boer NK; Rubin DT; Bouma G; Harrell LE; van Bodegraven AA
    Inflamm Bowel Dis; 2013 Feb; 19(2):363-9. PubMed ID: 22605661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
    Haines ML; Ajlouni Y; Irving PM; Sparrow MP; Rose R; Gearry RB; Gibson PR
    Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6-Thioguanine Nucleotide Levels Are Associated With Mucosal Healing in Patients With Crohn's Disease.
    Mao R; Guo J; Luber R; Chen BL; He Y; Zeng ZR; Ben-Horin S; Sparrow MP; Roblin X; Chen MH
    Inflamm Bowel Dis; 2018 Nov; 24(12):2621-2627. PubMed ID: 29788262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
    Spencer E; Norris E; Williams C; Dubinsky MC
    Inflamm Bowel Dis; 2019 Jan; 25(1):142-149. PubMed ID: 29920603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
    Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
    J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?
    Meijer B; Seinen ML; van Egmond R; Bouma G; Mulder CJJ; van Bodegraven AA; de Boer NKH
    Inflamm Bowel Dis; 2017 Nov; 23(11):2011-2017. PubMed ID: 28617756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study.
    Thomsen SB; Allin KH; Burisch J; Jensen CB; Hansen S; Gluud LL; Theede K; Kiszka-Kanowitz M; Nielsen AM; Jess T
    United European Gastroenterol J; 2020 Feb; 8(1):68-76. PubMed ID: 32213059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.